Venture Capitalists Fund New Generation of Alzheimer’s Drugs
After years of failure, drugmakers find success with medications for leading cause of dementia
By Brian Gormley
July 13, 2023 6:00 am ET | WSJ Pro
Alzheon, a biotech startup in Framingham, Mass., is developing a drug that blocks the formation of protein aggregates in the brain known as soluble amyloid oligomers, which damage neurons and their connections, according to the company. It expects data from a late-stage study of patients who have two copies of the APOE4 gene, the strongest genetic risk factor for Alzheimer’s, in the third quarter of 2024, CEO Dr. Martin Tolar said.